Efficacy and safety of mepolizumab in a Chinese population with severe asthma: a phase III, randomised, double-blind, placebo-controlled trial.

Ruchong ChenLiping WeiYuanrong DaiZaiyi WangDanrong YangMeiling JinCui XiongTing LiShuling HuJie SongRobert ChanSubramanya KumarAzza AbdelkarimNanshan Zhong

Published in: ERJ open research (2024)

Mepolizumab provided clinical benefits to patients with severe asthma in China and showed a favourable benefit-risk profile.

Keyphrases

double blind
phase iii
placebo controlled
clinical trial
open label
phase ii
study protocol
randomized controlled trial